These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32539491)

  • 21. Research suggests new drug targets for depression. Pilot studies of ketamine intrigue scientists, but risks of this anesthetic limit its clinical use.
    Harv Ment Health Lett; 2010 Nov; 27(5):6. PubMed ID: 21218614
    [No Abstract]   [Full Text] [Related]  

  • 22. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 23. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Gill H; Subramaniapillai M; Kratiuk K; Nasri F; Mansur RB; Rosenblat JD
    CNS Spectr; 2022 Jun; 27(3):322-330. PubMed ID: 33267928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral ketamine for depression: An updated systematic review.
    Meshkat S; Haikazian S; Di Vincenzo JD; Fancy F; Johnson D; Chen-Li D; McIntyre RS; Mansur R; Rosenblat JD
    World J Biol Psychiatry; 2023; 24(7):545-557. PubMed ID: 36651238
    [No Abstract]   [Full Text] [Related]  

  • 26. Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence.
    Di Vincenzo JD; Lipsitz O; Rodrigues NB; Jones BDM; Gill H; Lee Y; Lui LMW; Teopiz KM; Ho R; Lin K; Nasri F; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2022 Jan; 307():114321. PubMed ID: 34890909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression.
    Parikh SV; Vande Voort JL; Yocum AK; Achtyes E; Goes FS; Nykamp L; Singh B; Lopez-Vives D; Sera CE; Maixner D; Tarnal V; Severe J; Bartek S; Tye SJ; Rico J; Stoppel CJ; Becerra A; Smart L; Miller CR; Frye MA; Greden JF; Bobo WV
    J Affect Disord; 2024 Mar; 348():143-151. PubMed ID: 38142892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
    Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
    Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
    Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
    J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis.
    Włodarczyk A; Cubała WJ
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32050466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Cha DS; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
    J Psychiatr Res; 2021 Apr; 136():444-451. PubMed ID: 32948309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
    Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
    J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
    Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
    J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketamine-induced affective switch in a patient with treatment-resistant depression.
    Banwari G; Desai P; Patidar P
    Indian J Pharmacol; 2015; 47(4):454-5. PubMed ID: 26288483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
    Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.
    Cullen KR; Amatya P; Roback MG; Albott CS; Westlund Schreiner M; Ren Y; Eberly LE; Carstedt P; Samikoglu A; Gunlicks-Stoessel M; Reigstad K; Horek N; Tye S; Lim KO; Klimes-Dougan B
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):437-444. PubMed ID: 30004254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
    Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
    J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do the dissociative side effects of ketamine mediate its antidepressant effects?
    Luckenbaugh DA; Niciu MJ; Ionescu DF; Nolan NM; Richards EM; Brutsche NE; Guevara S; Zarate CA
    J Affect Disord; 2014 Apr; 159():56-61. PubMed ID: 24679390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.